Identity & applicability

Regulatory recordSupporting passage inspected

TB-500 in FDA’s review is a thymosin beta-4 fragment, not full-length thymosin beta-4. The agency did not identify human exposure or pharmacokinetic evidence for the fragment; studies of the parent peptide cannot establish fragment-specific injury-recovery effects.^[1]

Research-market use of the name may be inconsistent, and product identity requires chemical confirmation.

Inspection history

Clinical review: not reviewed by a qualified clinician.

2026-09-08 · Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.

2026-09-09 · Fresh scoped source inspection; locator/date corrections and original full-text evidence recorded. Independent editorial review pending; no qualified clinical review.

2026-09-09 · Independent editorial worker reopened the cited support; coordinator resolved the requested bibliography corrections and integrated the bounded claim. Original and corrected cell figures remain scientifically inconsistent as stated. No qualified clinical review.

Clinical & experimental findings

Regulatory recordSupporting passage inspected

FDA's review describes a laboratory scratch assay in which TB-500 did not significantly improve wound closure at the tested concentration, while one metabolite did. This limited experiment does not establish either clinical effectiveness or clinical ineffectiveness.^[1]

The original full experimental paper was not obtained; this claim reports the regulator's extraction.
A single-concentration cell assay is distinct from injury healing in animals or humans.

Inspection history

Clinical review: not reviewed by a qualified clinician.

2026-09-09 · Fresh source inspection of specified original sections; proposed addition awaits independent editorial review.

2026-09-09 · Independent editorial worker reopened the cited support; coordinator resolved the requested bibliography corrections and integrated the bounded claim. Original and corrected cell figures remain scientifically inconsistent as stated. No qualified clinical review.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Used FDA’s 2026 exact-fragment review and explicitly separated parent-peptide studies.

Exact-fragment human efficacy, kinetics and clinical safety remain unresolved.
Other inherited assertions not supported by the published claim set remain unverified; no qualified clinician review has occurred.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

FDA July 2026 Pharmacy Compounding Advisory Committee briefing: Thymosin beta-4 fragment (TB-500)
US Food and Drug Administration. 2026-07. Regulatory document.
Inspected location: PDF p. 25, Figure 5; PDF pp. 26–27, nonacetylated comparator/Rahaman scratch assay; PDF pp. 29–31, human exposure/PK and safety
Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts

peptide-fda-tb500-2026: Identity and Figure 5, PDF p. 25; human exposure and effectiveness, PDF pp. 29–30
July 23–24, 2026 FDA compounding advisory meeting page checked; committee review distinguished from approval.

View this compound in the research library →

Related records in this class

Grouped under Peptides for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.